Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe
Insulet (NASDAQ: PODD) has expanded the availability of its Omnipod 5 Automated Insulin Delivery System to five additional European countries: Italy, Denmark, Finland, Norway, and Sweden. The system is now compatible with both Abbott's FreeStyle Libre 2 Plus and Dexcom G6 Continuous Glucose Monitoring sensors, making it the first and only tubeless automated insulin delivery system integrated with both leading CGM sensor brands.
The Omnipod 5 system, indicated for individuals aged two years and older with type 1 diabetes, is currently the number one insulin pump for new users in Europe and the most prescribed AID system in the U.S. The system is waterproof and features proactive glucose control. Clinical results and real-world evidence have shown improvements in A1c levels and time in range while maintaining low hypoglycemia rates.
Insulet (NASDAQ: PODD) ha ampliato la disponibilità del suo Omnipod 5 Sistema di Somministrazione Automatica di Insulina in cinque paesi europei aggiuntivi: Italia, Danimarca, Finlandia, Norvegia e Svezia. Il sistema è ora compatibile sia con il FreeStyle Libre 2 Plus di Abbott che con i sensori di Monitoraggio Continuo della Glucosio Dexcom G6, rendendolo il primo e unico sistema di somministrazione automatica di insulina senza tubi integrato con entrambi i principali marchi di sensori CGM.
Il sistema Omnipod 5, indicato per individui di età pari o superiore a due anni con diabete di tipo 1, è attualmente la pompa per insulina numero uno per nuovi utenti in Europa e il sistema AID più prescritto negli Stati Uniti. Il sistema è impermeabile e presenta un controllo glicemico proattivo. I risultati clinici e le prove nel mondo reale hanno mostrato miglioramenti nei livelli di A1c e nel tempo di avvicinamento, mantenendo bassi tassi di ipoglicemia.
Insulet (NASDAQ: PODD) ha ampliado la disponibilidad de su Sistema de Entrega Automática de Insulina Omnipod 5 a cinco países europeos adicionales: Italia, Dinamarca, Finlandia, Noruega y Suecia. El sistema ahora es compatible tanto con el FreeStyle Libre 2 Plus de Abbott como con los sensores de Monitoreo Continuo de Glucosa Dexcom G6, lo que lo convierte en el primer y único sistema de entrega automática de insulina sin tuberías integrado con ambas marcas líderes de sensores CGM.
El sistema Omnipod 5, indicado para personas mayores de dos años con diabetes tipo 1, es actualmente la bomba de insulina número uno para nuevos usuarios en Europa y el sistema AID más prescrito en los EE.UU. El sistema es impermeable y cuenta con un control proactivo de la glucosa. Los resultados clínicos y la evidencia del mundo real han mostrado mejoras en los niveles de A1c y en el tiempo en rango, manteniendo bajas tasas de hipoglucemia.
인슐렛 (NASDAQ: PODD)은 오므니팟 5 자동 인슐린 전달 시스템의 가용성을 이탈리아, 덴마크, 핀란드, 노르웨이, 스웨덴 등 5개 유럽 국가로 확장했습니다. 이 시스템은 이제 Abbott의 FreeStyle Libre 2 Plus와 Dexcom G6 연속 혈당 모니터링 센서와 호환되어, 두 가지 주요 CGM 센서 브랜드와 통합된 최초이자 유일한 튜브 없는 자동 인슐린 전달 시스템이 되었습니다.
오므니팟 5 시스템은 2세 이상의 제1형 당뇨병 환자를 위해 설계되었으며, 현재 유럽에서 신규 사용자에게 가장 많이 사용되는 인슐린 펌프이자 미국에서 가장 많이 처방되는 AID 시스템입니다. 이 시스템은 방수 기능이 있으며, 적극적인 혈당 조절 기능을 제공합니다. 임상 결과와 실제 데이터는 A1c 수치와 목표 범위 내 시간의 개선을 보여주면서 낮은 저혈당 비율을 유지하고 있음을 나타냅니다.
Insulet (NASDAQ: PODD) a élargi la disponibilité de son Système de Livraison Automatique d'Insuline Omnipod 5 à cinq pays européens supplémentaires : Italie, Danemark, Finlande, Norvège et Suède. Le système est maintenant compatible à la fois avec le FreeStyle Libre 2 Plus d'Abbott et les capteurs de Surveillance Continue de la Glucose Dexcom G6, ce qui en fait le premier et le seul système de livraison automatique d'insuline sans tube intégré avec les deux principales marques de capteurs CGM.
Le système Omnipod 5, destiné aux personnes âgées de deux ans et plus atteintes de diabète de type 1, est actuellement la pompe à insuline la plus utilisée par les nouveaux utilisateurs en Europe et le système AID le plus prescrit aux États-Unis. Le système est étanche et dispose d'un contrôle proactif de la glucose. Les résultats cliniques et les preuves du monde réel ont montré des améliorations des niveaux d'A1c et du temps passé dans la plage tout en maintenant de faibles taux d'hypoglycémie.
Insulet (NASDAQ: PODD) hat die Verfügbarkeit seines Omnipod 5 Automatisches Insulin Abgabesystem auf fünf zusätzliche europäische Länder ausgeweitet: Italien, Dänemark, Finnland, Norwegen und Schweden. Das System ist jetzt sowohl mit Abbotts FreeStyle Libre 2 Plus als auch mit Dexcom G6 kontinuierlichen Glukosemonitoren kompatibel und ist damit das erste und einzige tubuslose automatische Insulinabgabesystem, das mit beiden führenden CGM-Sensor-Marken integriert ist.
Das Omnipod 5-System, das für Personen ab zwei Jahren mit Typ-1-Diabetes angegeben ist, ist derzeit die Nummer eins Insulinpumpe für neue Benutzer in Europa und das meistverschriebene AID-System in den USA. Das System ist wasserdicht und bietet eine proaktive Glukosekontrolle. Klinische Ergebnisse und reale Beweise haben Verbesserungen der A1c-Werte und der Zeit im Zielbereich gezeigt, während die Hypoglykämieraten niedrig gehalten werden.
- Market leadership: #1 insulin pump for new users in Europe and #1 prescribed AID system in U.S.
- Geographic expansion into 5 new European markets
- Dual compatibility with leading CGM sensors (Abbott and Dexcom)
- Demonstrated clinical efficacy with improved A1c and time in range outcomes
- First and only tubeless automated insulin delivery system with dual CGM compatibility
- None.
Insights
The expansion of Omnipod 5 into five additional European markets represents a strategic market penetration that significantly broadens Insulet's addressable patient population. The system's dual CGM compatibility with both Abbott's FreeStyle Libre 2 Plus and Dexcom G6 is a important differentiator, effectively capturing the entire CGM market share. This flexibility in sensor choice removes a major barrier to adoption and should accelerate market penetration.
The company's position as the number one insulin pump for new users in Europe and the most prescribed AID system in the U.S. demonstrates strong market acceptance and positions Insulet favorably for continued growth. The waterproof feature and tubeless design address key patient pain points, particularly important in the European market where active lifestyles and discretion in medical device wear are highly valued.
Real-world evidence from 69,902 Type 1 diabetes patients provides robust validation of the system's clinical benefits, which is important for securing favorable reimbursement decisions in European healthcare systems. The expansion timing is optimal, capitalizing on the growing adoption of AID systems in diabetes care.
The European diabetes device market represents a substantial growth opportunity, with these five new countries adding approximately 300,000 Type 1 diabetes patients to Insulet's addressable market. The Nordic countries, in particular, have high adoption rates for diabetes technology and favorable reimbursement policies, which should support rapid market penetration.
Insulet's strategic decision to launch with dual CGM compatibility addresses a critical market dynamic - the regional variations in CGM brand preferences across European countries. This flexibility allows Insulet to adapt to local market conditions and healthcare provider preferences, potentially accelerating adoption rates and market share gains.
The timing of this expansion, following successful launches in major markets like the UK, Germany and France, suggests a well-executed market entry strategy. The company's status as the preferred choice for new pump users indicates strong product-market fit and effective marketing strategies, which should translate into sustained revenue growth in these new territories.
The Omnipod 5 Automated Insulin Delivery System is now commercially available in
Omnipod 5 is now available with both Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 Continuous Glucose Monitoring (CGM) sensor compatibility. Indicated for individuals aged two years and older with type 1 diabetes, Omnipod 5 is the first and only tubeless automated insulin delivery (AID) system integrated with both leading CGM sensor brands.
“We are excited to bring our flagship Omnipod 5 AID System to more people across Europe,” said Patrick Crannell, Insulet Senior Vice President and International General Manager. “Following our successful launches of Omnipod 5 in the
Omnipod is recognized as the number one insulin pump for new pump users in
"I can’t wait to get my Omnipod 5 so I can think less about diabetes,” said Lina, a 45-year-old resident of
Sensor integration with Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 allows many users to benefit from Omnipod 5 with their sensor of choice. It also gives prescribers more flexibility when recommending a sensor for their patients, making it fast and easy to start AID therapy with Omnipod 5.
“Omnipod 5 with two sensor choices is going to change lives for people living with type 1 diabetes in
To learn more or to get started, visit the Omnipod website.
1 Omnipod was the most frequently chosen pump in the past year among people new to an insulin pump in a survey conducted by dQ&A across
2
3 The Pod has an IP28 rating for up to 7.6 meters (25 feet) for 60 minutes. The Omnipod® 5 controller is not waterproof. The Dexcom G6 sensor and transmitter are water-resistant and may be submerged under 2.4 meters (8 feet) of water for up to 24 hours without failure when properly installed. The FreeStyle Libre 2 Plus sensor is water-resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes.
4 Sherr JL, et al. Diabetes Care (2022). Study in 80 people with type 1 diabetes (T1D) aged 2 - 5.9 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode.
5 Brown et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 - 70 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode.
6 Forlenza GP et al. Diabetes Technology & Therapeutics (2024). Real-World Evidence of Omnipod 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in
©2025 Insulet Corporation. Omnipod and Podder are registered trademarks of Insulet Corporation. All rights reserved. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. Dexcom is a registered trademark of Dexcom, Inc. and used with permission. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113217259/en/
Investor Relations:
June Lazaroff
Senior Director, Investor Relations
(978) 600-7718
jlazaroff@insulet.com
Media:
Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com
Source: Insulet Corporation
FAQ
Which new European countries now have access to Insulet's Omnipod 5 (PODD)?
What CGM sensors are compatible with the Omnipod 5 system (PODD)?
What are the key clinical benefits of the Omnipod 5 system (PODD)?
What is the minimum age requirement for Omnipod 5 (PODD) usage?
What is Omnipod 5's (PODD) market position in Europe and the US?
